Latest Safety News

Paladin Energy Ltd has launched a significant A$300 million underwritten equity raising to advance its Patterson Lake South uranium project and support the ramp-up of its Langer Heinrich Mine, reinforcing its position in the global uranium market.

Brightstar Resources reports underground mining operations at its Laverton Hub are significantly ahead of schedule, targeting a +50% quarter-on-quarter production increase in the September quarter. The Fish Mine has turned cash flow positive, underpinning a robust growth outlook.

Tesoro Gold has released an expanded and upgraded scoping study for its Ternera open pit project in Chile, revealing strong economics and a 1.82 million ounce gold resource. The study highlights a straightforward development path with low capital costs and excellent gold recoveries.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Paladin Energy has launched a fully underwritten A$300 million equity raising to advance its Patterson Lake South uranium project, aiming for a Final Investment Decision and first production by 2031.

First Graphene’s UK partner Vector Group has filed patents for novel fire-resistant materials enhanced with PureGRAPH graphene, showing 100% self-extinguishing performance and improved safety for construction.

New Hope Group’s FY25 results reveal a robust increase in coal production and improved safety, alongside steady shareholder dividends and strategic capital management.

New Hope Corporation Limited posted a slight dip in revenue and net profit for FY2025 but achieved a notable 18% rise in saleable coal production, driven by growth at New Acland Mine and steady output at Bengalla Mine.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Alterity Therapeutics has unveiled encouraging Phase 2 trial results for ATH434, demonstrating its potential to slow disease progression in Multiple System Atrophy while maintaining a strong safety profile.

Spacetalk Ltd has raised $4.05 million through a combination of a conditional placement and convertible notes to accelerate its geographic expansion and app development, alongside appointing a seasoned director to its board.

Actinogen Medical has reached a pivotal agreement with the US FDA outlining the regulatory and clinical trial requirements for Xanamem’s approval in Alzheimer’s disease, setting a clear path toward a US marketing application.